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plications were derived from the DCCT, Framingham, and
WESDR studies. Clinical input was taken from the 26-week mul-
ticenter, multinational, open-label trial. Costs were retrieved
from published sources. Direct and indirect costs of diabetes
complications and treatment with IDet/IAsp or IGlar/IAsp were
projected over patients’ lifetimes from a societal health care per-
spective. Costs and outcomes were discounted at 3.5% annually.
RESULTS: In this analysis, a reduction in major hypoglycemic
events associated with IDet/IAsp led to an increase in quality-
adjusted life expectancy of 0.11 quality-adjusted life years
(QALYs). Direct lifetime costs were slightly higher with
IDet/IAsp treatment than with IGlar/IAsp treatment, leading to
ICURs of €21,455 per QALY gained in Austria and €13,607 per
QALY gained in Germany. When indirect costs were included 
in the analysis, IDet/IAsp was dominant to IGlar/IAsp in both
countries. CONCLUSIONS: IDet/IAsp therapy was associated
with improved quality-adjusted life expectancy, leading to an
ICUR based on direct costs that was well within the range 
considered to represent good value for money in Austria and
Germany.
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OBJECTIVES: Forty percent of hypertensive type-2 diabetes
patients will develop nephropathy, indicating end organ damage,
increased risk of cardiovascular disease (CVD), and death. In the
US, screening rates and nephropathy treatment are suboptimal.
We assessed the health economic impact of nephropathy screen-
ing followed by optimal antihypertensive therapy in those who
have nephropathy in the US. METHODS: A Markov/Monte
Carlo model simulated lifetime impacts of screening for
nephropathy using semi-quantitative urine dipsticks in a primary
care setting, and subsequent addition of irbesartan 300mg to
conventional antihypertensives in hypertensive type-2 diabetes
patients in those patients identiﬁed as having nephropathy. Pro-
gression from no renal disease to end-stage renal disease (ESRD)
was simulated. Probabilities, utilities and costs of CVD events,
medications and ESRD treatment came from published sources.
Number of days of ESRD avoided, quality-adjusted life years
(QALYs) and direct costs were projected. Second-order Monte
Carlo simulation was used to account for uncertainty in multi-
ple parameters. Costs and QALYs were discounted three percent
annually. RESULTS: Screening followed by optimized treatment
led to 36,683 ± 5767 days of ESRD avoided in 1000 simulated
patients, with incremental costs per QALY gained of $7315.
There was a 98% probability that screening and optimized anti-
hypertensive therapy would be considered cost-effective with a
willingness to pay ≥$20,000. Sensitivity analysis showed that
screening and optimized treatment would dominate “no screen-
ing” in patients <55 years of age. CONCLUSIONS: In hyper-
tensive patients with type-2 diabetes, screening for albuminuria
followed by optimal antihypertensive treatment is cost-effective
in a US setting.
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INTRODUCTION: Diabetes increases resource use, and com-
plications add to costs. The purpose of this study was to char-
acterise the association between increasing frequency and
severity of the symptoms of diabetic peripheral neuropathy
(SDPN), measured by the Neuropathy Total Symptom Score
(NTSS)-6-SA, and health care resource use and loss of produc-
tivity. METHODS: A postal survey was mailed to subjects iden-
tiﬁed at random from hospital records as having either type-1 or
Type-2 diabetes using the same methods as the Health Outcomes
Data Repository (HODaR). Cross-sectional, univariate and mul-
tivariate analyses were used to test for the associations in this
preliminary analysis of the ﬁrst 604 responses. Where appropri-
ate, four categories were used for cross-sectional analysis based
on quartiles of the NTSS-6-SA scores, Q1 being the lowest score.
RESULTS: The mean age of respondents was 64 years (IQR
55–73); 58% male and the mean duration of diabetes were 14
years (IQR 5–18). 24% reported no SDPN symptoms. The mean
number of days in hospital in the previous year was: Q1 = 3.4
and Q4 = 8.3. Mean number of ambulatory care in last year: Q1
= 4.4 and Q4 = 10.6. Mean contacts with a GP or nurse in the
community over six months: Q1 = 6.0 and Q4 = 14.3. Mean
productive days lost in the previous six months: Q1 = 35 and
Q4 = 128 (note: multiple categories can occur on the same day).
In multivariate analysis adjusting for age and other complica-
tions, the NTSS-6-SA score remained highly signiﬁcant. Using
days in hospital since 1995 (10 years) as the dependent variable,
there was an increase of 0.3 days per NTSS-6-SA unit (p <
0.001), and using outpatient attendances since 1997 as the
dependent variable (8 years), there was an increase of 1.13 visits
per unit (p < 0.001). CONCLUSIONS: There was a direct asso-
ciation between increase SDPN and increasing health care
resource use; furthermore, increasing SDPN was associated with
lost productivity.
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Diabetes Mellitus is a signiﬁcant public health problem in the
United States. Monitoring of glycmeic status, eye exam, LDL-C
levels, and nephropathy testing is essential for diabetes care.
OBJECTIVES: To improve diabetic care within a Medicaid
Managed Care Organization. METHODS: This is a prospective
interventional, pre- and post comparison study with retrospec-
tive claims data and medical chart review. Four indicators:
HbA1c, LDL-C, eye exam, and nephropathy monitoring were
targeted for quality improvement interventions. A random
sample of 411 diabetic members aged 18–75 years was selected
using administrative and medical records. Patient demographics,
past medical history, eye exam, and laboratory data were
recorded using a standard form. Patient and provider interven-
tions included: case manager phone outreach program to remind
